Brother Technology announced in the morning that Brother Pharmaceuticals, a wholly-owned subsidiary, has received a notice of approval for the marketing application of iohydrol, which means that the company can manufacture and sell in the domestic market, which has a positive impact on the production capacity release and further market expansion of the company's iodide contrast agent API project.
兄弟科技：子公司收到碘海醇原料药上市申请批准通知书
Brother Technology: The subsidiary received a notice of approval for the marketing application of iohexol as an API
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.